
    
      The primary objective of the study was to demonstrate the efficacy of Z102 (2.7 mg
      prednisolone/360 mg dipyridamole) versus placebo on the Disease Activity Score 28 using C
      reactive protein (DAS28-CRP) in subjects with rheumatoid arthritis at the study endpoint of
      12 weeks
    
  